Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Expectations By $0.03 EPS

Denali Therapeutics (NASDAQ:DNLI) announced its earnings results on Wednesday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03), Briefing.com reports. During the same period last year, the business posted ($0.72) EPS.

Denali Therapeutics Stock Performance

DNLI traded up $0.46 on Friday, hitting $30.06. 107,778 shares of the company were exchanged, compared to its average volume of 1,068,161. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13. The firm has a market capitalization of $4.30 billion, a P/E ratio of -10.39 and a beta of 1.40. The business’s fifty day moving average is $27.67 and its 200 day moving average is $23.40.

Insider Activity

In related news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares in the company, valued at $844,656.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday. Bank of America lifted their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Jefferies Financial Group upped their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.